Techcyte's digital diagnostics platform applies the latest in convolutional neural networks to assist ARUP's staff in delivering fast and accurate results to doctors and patients.
The platform supports a range of whole slide scanners as well as multiple tests, such as blood differential, cervical cytology, fine needle aspiration, ova and parasites (fecal), urinalysis, and bacteriology.
The collaboration between ARUP and Techcyte will significantly accelerate the number of new test algorithms available to the lab diagnostic market.
ARUP's vast expertise and access to rare samples combined with Techcyte's data-pipeline and machine-learning experts will produce high-quality algorithms that can be developed quickly and then introduced into the market following thorough testing.
Medical labs, hardware manufacturers, hospitals, and clinics will all benefit from Techcyte's solutions. In 2019, Techcyte will deliver solutions for blood analysis, fecal ova and parasites, cervical cytology and bacteriology. Additional tests will be announced when they are ready for market use.
Headquartered in Orem, Utah, Techcyte, Inc. was founded in 2013 as a technology transfer from the University of Utah with a mission to lower healthcare costs through artificial intelligence.
Techcyte uses the power of deep machine learning to perform image analysis of whole slide images. Image analysis is required for widespread adoption of digital pathology in research, pharma, human, air quality and veterinary diagnostic testing.
ARUP Laboratories is a national clinical and anatomic pathology reference laboratory and a worldwide leader in innovative laboratory research and development.
A nonprofit enterprise of the University of Utah, ARUP offers an extensive test menu of highly complex and unique medical tests.
Rather than competing with its clients for physician office business, ARUP chooses instead to support clients' existing test menus by offering highly complex and unique lab tests, with accompanying consultative support, to enhance their abilities to provide laboratory services.
GSK releases decade-long data on Shingrix efficacy
GSK announces positive EAGLE-1 results for gepotidacin in gonorrhoea treatment
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
Charles River Laboratories launches AMAP to reduce animal testing reliance
PureTech completes enrollment in Phase 2b ELEVATE IPF trial for LYT-100
Cybin secures additional US patent for CYB003 breakthrough therapy programme
UroGen's UGN-103 IND accepted by FDA for bladder cancer treatment
Biophytis reinforces obesity IP with new patent application
MaaT Pharma reveals positive 18-month data for MaaT013 in GI-aGvHD
Fusion Antibodies plc secures contract for OptiPhage library development
Innate Pharma advances Sanofi-developed NK cell engager to Phase 2 for blood cancer patients